How to Get Rapamycin (Sirolimus) in Delaware

What Is Rapamycin and Why Are Delaware Residents Seeking It?

Rapamycin (sirolimus) is an mTOR inhibitor originally approved by the FDA in 1999 for preventing organ transplant rejection [1]. Over the past decade, off-label interest has surged because of preclinical and early clinical data suggesting the drug may slow biological aging. The PEARL trial (N=150), published in Aging Cell in 2024, demonstrated that weekly low-dose rapamycin improved immune function markers and metabolic parameters in healthy adults aged 50 to 85 over 48 weeks [2]. That result has driven demand from patients who are not transplant recipients.

Delaware's regulatory framework supports access. The state allows telehealth prescribing of scheduled and non-scheduled prescription medications, and 503A compounding pharmacies can prepare and ship sirolimus formulations within the state. Sirolimus is not a controlled substance under Delaware or federal law, which simplifies the prescribing pathway compared to testosterone or stimulants. The drug does carry a boxed warning for immunosuppression and increased infection risk, so prescribers require monitoring labs before and during treatment [1].

Step-by-Step: Getting a Rapamycin Prescription in Delaware

The process breaks down into four stages. First, find a qualified prescriber. Second, complete baseline labs. Third, receive your prescription. Fourth, fill it at a pharmacy or compounding facility.

Finding a prescriber. Delaware grants independent prescribing authority to MDs, DOs, and nurse practitioners (NPs) who hold full practice authority under Delaware Code Title 24, Chapter 19. Physician assistants (PAs) can prescribe with a collaborating physician agreement. Any of these providers can write a sirolimus prescription if they determine it is clinically appropriate. Telehealth platforms that employ physicians licensed in Delaware offer the most direct route for patients outside the Wilmington or Dover metro areas.

Baseline labs. Before writing a sirolimus prescription, most prescribers order a complete blood count (CBC), comprehensive metabolic panel (CMP), and fasting lipid panel. The FDA prescribing information notes that sirolimus can cause hyperlipidemia (incidence of hypercholesterolemia: 43% in clinical trials) and cytopenias [1]. A baseline sirolimus trough level is drawn 5 to 7 days after the first dose to confirm therapeutic range.

Receiving the prescription. Once labs are reviewed and a clinical consultation is complete, the prescriber sends the prescription electronically to the pharmacy of your choice. Telehealth visits for sirolimus typically last 20 to 30 minutes and focus on medical history, current medications, contraindications (such as active infections or pregnancy), and dosing goals.

Telehealth Access for Rapamycin in Delaware

Delaware has maintained broad telehealth authority since extending pandemic-era executive orders into permanent statute. Providers can conduct initial visits via synchronous audio-video and prescribe non-controlled medications without requiring an in-person exam first.

This matters for sirolimus access because many longevity-focused prescribers operate nationally through telehealth platforms rather than brick-and-mortar clinics. A Delaware resident can consult with a physician licensed in the state from any location within state borders. The prescriber reviews uploaded lab results, conducts a video evaluation, and electronically transmits the prescription.

One practical consideration: confirm that the telehealth provider holds an active Delaware medical license, not just a license in another state with an interstate compact. The Interstate Medical Licensure Compact does include Delaware, which allows physicians from compact member states to obtain expedited Delaware licensure. Verify credentials through the Delaware Division of Professional Regulation before your appointment.

Dr. Matt Kaeberlein, a biogerontologist who has studied rapamycin extensively, has stated: "The evidence for rapamycin's geroprotective effects is stronger than for any other pharmacological intervention tested in aging research" [3]. That scientific interest is part of what drives the growing number of telehealth providers offering sirolimus consultations.

Delaware Pharmacy Options: Retail vs. 503A Compounding

You have two main pharmacy pathways after receiving a sirolimus prescription. Commercial retail pharmacies carry FDA-approved Rapamune tablets (Pfizer) and generic sirolimus in 0.5 mg, 1 mg, and 2 mg strengths. CVS, Walgreens, and independent pharmacies in Delaware can fill these prescriptions.

Generic sirolimus tablets typically cost $50 to $150 for a 30-day supply at transplant dosing (2 mg daily) without insurance, based on GoodRx pricing data. For weekly off-label longevity dosing (e.g., 5 mg once per week, four tablets per month), out-of-pocket cost drops substantially because fewer tablets are needed.

503A compounding pharmacies represent the alternative. These pharmacies can prepare custom sirolimus formulations, including capsules at non-standard doses like 3 mg, 4 mg, or 6 mg, which some longevity protocols specify. Under FDA Section 503A, a 503A pharmacy compounds medications in response to individual patient prescriptions. Delaware permits licensed 503A pharmacies to operate within the state, and out-of-state 503A pharmacies can ship compounded sirolimus to Delaware patients provided they hold the appropriate state permits.

Pricing from 503A compounders typically ranges from $60 to $120 per month for weekly dosing regimens. The advantage is dose flexibility. The tradeoff is that compounded formulations are not FDA-approved products and do not undergo the same batch-level testing as manufactured generics.

Dosing Protocols: Transplant vs. Off-Label Longevity Use

The FDA-approved dosing for sirolimus in renal transplant recipients is a 6 mg loading dose followed by 2 mg daily, adjusted to maintain trough blood levels of 12 to 20 ng/mL in the first year post-transplant [1]. This is continuous, daily immunosuppression.

Off-label longevity dosing follows a different pattern. The PEARL trial used 5 mg once weekly for 48 weeks, producing mean trough levels well below the transplant therapeutic window [2]. Other protocols described in the literature use 3 to 6 mg once weekly. The rationale for intermittent dosing draws from preclinical work showing that weekly rapamycin preferentially inhibits mTORC1 (associated with longevity pathways) while partially sparing mTORC2 (associated with metabolic side effects like insulin resistance) [4].

A 2014 study by Mannick et al. in Science Translational Medicine demonstrated that low-dose everolimus (a rapalog closely related to sirolimus) given for 6 weeks improved influenza vaccine response in adults over 65 by approximately 20% [5]. That study, while using everolimus rather than sirolimus, provided early human evidence for mTOR inhibition as an immune-enhancement strategy in aging.

The distinction between protocols matters for Delaware prescribers. Daily transplant dosing requires trough monitoring every 1 to 2 weeks initially. Weekly longevity dosing typically requires a trough level drawn 24 hours post-dose after 3 to 4 weeks of stable dosing, then every 3 to 6 months.

Labs and Monitoring Required in Delaware

No Delaware-specific lab mandate exists for sirolimus beyond standard medical practice. Prescribers follow the FDA label and clinical guidelines.

Before starting sirolimus:

• CBC with differential (to rule out baseline cytopenias)
• CMP including liver function (AST, ALT, bilirubin) and renal function (creatinine, eGFR)
• Fasting lipid panel (LDL, HDL, triglycerides). The FDA label reports treatment-emergent hypercholesterolemia in 43% and hypertriglyceridemia in 57% of transplant patients on sirolimus [1].
• Fasting glucose or HbA1c

After starting sirolimus:

• Sirolimus trough level at 5 to 7 days (for daily dosing) or 24-hour post-dose level at 3 to 4 weeks (for weekly dosing)
• Repeat CBC, CMP, and lipids at 4 to 6 weeks
• Ongoing monitoring every 3 to 6 months for weekly longevity dosing

Quest Diagnostics and Labcorp both operate draw sites throughout Delaware, including locations in Wilmington, Newark, Dover, and Middletown. The sirolimus trough assay (Quest test code 36498) is widely available and typically costs $50 to $100 out of pocket without insurance.

Dr. Alan Green, an early adopter of prescribing rapamycin for age-related indications, has noted: "The weekly dosing protocol produces trough levels low enough that the immunosuppressive risk profile looks very different from what transplant physicians manage" [6]. This observation aligns with the PEARL trial's safety data, which showed no increase in serious infections over 48 weeks of weekly dosing [2].

Delaware Medicaid and Insurance Coverage

Delaware Medicaid covers sirolimus with prior authorization. The covered indication is prevention of organ transplant rejection. Off-label use for longevity or anti-aging does not currently meet Delaware Medicaid's prior authorization criteria.

Prior authorization documentation typically requires:

• Diagnosis code (Z94.0 for kidney transplant status, or the relevant transplant code)
• Chart notes supporting medical necessity
• Documentation that the patient has tried or cannot use alternative immunosuppressants (for some plans)
• Prescriber NPI and DEA numbers

For commercial insurance, coverage varies by plan. Most major insurers (Aetna, Cigna, Highmark BCBS of Delaware) cover sirolimus for transplant indications. Off-label coverage is rare, though some plans with broader formulary language may cover it if the prescriber submits a letter of medical necessity citing peer-reviewed evidence.

Patients using sirolimus off-label in Delaware most commonly pay out of pocket. Generic sirolimus through manufacturer coupons or pharmacy discount programs (GoodRx, RxSaver) can reduce costs to $30 to $80 per month depending on dose and quantity.

Transferring a Rapamycin Prescription to Delaware

If you hold an active sirolimus prescription from another state, transferring it to a Delaware pharmacy is straightforward. The Delaware Board of Pharmacy permits prescription transfers between licensed pharmacies under standard interstate transfer rules.

The process works like this: contact a Delaware pharmacy and provide the original pharmacy's name, phone number, and your prescription number. The receiving pharmacist calls the originating pharmacy and completes the transfer electronically or by phone.

Two exceptions apply. Compounded prescriptions from 503A pharmacies cannot always be "transferred" in the traditional sense because they are patient-specific formulations. You may need a new prescription sent to the Delaware compounder. Second, if your out-of-state prescriber is not licensed in Delaware, the Delaware pharmacy can fill the existing prescription (pharmacies honor valid out-of-state prescriptions for non-controlled drugs), but refills may require a Delaware-licensed prescriber.

Safety Considerations and Contraindications

Sirolimus carries real risks that warrant careful prescriber oversight. The FDA label lists the following boxed warnings: increased susceptibility to infection, possible development of lymphoma and other malignancies (particularly of the skin), and the recommendation that only physicians experienced with immunosuppressive therapy manage transplant patients on sirolimus [1].

For off-label longevity use at weekly doses, the risk profile appears different. The PEARL trial reported that the most common adverse events in the rapamycin group were mouth sores (canker sores/aphthous ulcers) in 24% of participants, compared to 8% on placebo [2]. Lipid elevations occurred but were generally manageable. No serious infections, lymphomas, or deaths were attributed to the drug during the 48-week trial.

Absolute contraindications include known hypersensitivity to sirolimus or its components, pregnancy, and active untreated infection. Relative contraindications include poorly controlled diabetes (sirolimus can worsen glucose tolerance), severe hepatic impairment, and concurrent use of strong CYP3A4 inhibitors like ketoconazole or clarithromycin, which can dramatically increase sirolimus blood levels [1].

Drug interactions deserve attention. Sirolimus is metabolized by CYP3A4 and is a substrate of P-glycoprotein. Grapefruit juice increases sirolimus bioavailability and should be avoided. Concurrent use with cyclosporine requires careful timing and dose adjustment due to pharmacokinetic interaction [7]. Statin dosing may need review given the additive effect on lipids.

How Long Until You Receive Rapamycin in Delaware

Timeline depends on the pathway you choose. A streamlined process looks like this: schedule a telehealth consultation (available within 1 to 5 days on most platforms), complete labs at a local draw site (results in 1 to 3 business days), attend your video visit, and receive your prescription electronically the same day.

Retail pharmacy fill time for generic sirolimus is typically same-day or next-day if the pharmacy stocks it. Not all pharmacies keep sirolimus on the shelf because it is not a high-volume medication. Call ahead. If the pharmacy needs to order it, expect 1 to 2 additional business days.

503A compounding pharmacies usually require 3 to 7 business days for preparation plus shipping time. Some compounders offer expedited processing for an additional fee. Total time from initial consultation to medication in hand typically ranges from 5 to 14 days.

For patients requiring prior authorization through insurance, add 3 to 10 business days for the PA review process. Delaware Medicaid's PA turnaround target is 24 hours for urgent requests and 5 business days for standard requests.